Autolus reiterates $120M-$135M AUCATZYL revenue target for 2026 while expanding pivotal trial pipeline
Source: SeekingAlpha
2026-03-27 14:26:56 ET
More on Autolus Therapeutics
- Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
- Autolus Therapeutics plc 2025 Q4 - Results - Earnings Call Presentation
- Autolus Therapeutics FY 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Autolus Therapeutics
- Historical earnings data for Autolus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Autolus reiterates $120M–$135M AUCATZYL revenue target for 2026 while expanding pivotal trial pipeline
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
21.09% G/L:
$1.9071 Last:
2,034,566 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
